Progress toward New Medicines and Vaccines
The biopharmaceutical industry utilizes its scientific and industrial expertise to build on and advance basic science research into safe and effective treatments and vaccines that can be made available to patients. The biopharmaceutical industry is uniquely positioned to take on the necessary risk to advance research into safe and effective treatments. For example:
Committed to Research
In 2017, PhRMA furthered its commitment to the development of new treatments and cures by establishing new R&D requirements for its member companies. All of PhRMA’s member companies now meet the following criteria:
- A three-year average global R&D to global sales ratio of 10% or greater; and
- A three-year average global R&D spending of at least $200 million per year.
PhRMA member companies have invested nearly $1 trillion dollars in R&D since 2000, establishing the biopharmaceutical sector as the most R&D-intensive industry in the U.S. economy. In fact, the biopharmaceutical industry invests on average six times more in R&D as a percentage of sales than all other manufacturing industries.
Through investment in R&D, biopharmaceutical researchers and scientists have gained a better understanding of diseases and a greater ability to harness new scientific advances, leading to tremendous progress in the development of treatments and cures for some of the most debilitating diseases patients face.